Physician profile
Wynn Sheade
NPI 1568511210
$1,751.07
in general payments reported to CMS, 2019-2025
20 companies · $237 in 2025
The $237 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $50.23 · 2021: $272 · 2022: $380 · 2023: $256 · 2024: $391 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $327.75 | 2019-2025 | |
| Sobi, INC | $197.58 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $138.16 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $125.42 | 2019-2023 | Vaxelis, Gardasil 9, M-M-R II |
| Glaxosmithkline, LLC. | $104.43 | 2019-2025 | Bexsero, Pediarix, Menveo |
| Cranial Technologies, INC | $92.15 | 2019-2024 | Doc Band |
| Pfizer INC. | $91.13 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $89.53 | 2021-2024 | Crysvita |
| Kaleo, INC. | $88.29 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $63.26 | 2021 | |
| Biomarin Pharmaceutical INC. | $59.92 | 2022-2024 | Voxzogo 1.2mg |
| Seqirus USA INC | $59.79 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Mirum Pharmaceuticals, INC. | $52.81 | 2023-2025 | Livmarli |
| Verrica Pharmaceuticals INC. | $49.63 | 2024 | Ycanth |
| Genentech USA, INC. | $47.10 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $44.61 | 2022 | |
| Alk-Abello, INC | $38.87 | 2025 | Neffy |
| Shire North American Group INC | $32.91 | 2019 | |
| Phadia US INC. | $26.73 | 2024 | Immunocap |
| Alexion Pharmaceuticals, INC. | $21.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wynn Sheade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.